GAUDIUMIVF

Gaudium IVF and Women Health Limited has informed the exchanges about the availability of the audio recording of its Earnings Call. The call discussed the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026, and was held on May 29, 2026. The recording is accessible on the company's website.

Consolidated Revenue from Operations ₹30.35 Cr vs ₹26.92 Cr (▲12.74% YoY), EBITDA ₹12.17 Cr vs ₹8.72 Cr (▲39.56% YoY), PAT ₹8.36 Cr vs ₹6.45 Cr (▲29.46% YoY). EBITDA Margin 40.10% vs 32.39% (▲771 bps). The company also integrated AI-led embryology platforms in April 2026 and plans expansion into new IVF hubs.

Gaudium IVF and Women Health Limited reported strong Q4 FY26 consolidated results. Revenue from operations increased to ₹30.35 Cr from ₹26.92 Cr (▲12.73% YoY). EBITDA grew to ₹12.17 Cr from ₹8.72 Cr (▲39.56% YoY), and Net Profit (PAT) rose to ₹8.36 Cr from ₹6.46 Cr (▲29.45% YoY). EBITDA margin expanded significantly to 40.11% from 32.39% (▲772bps).

Gaudium IVF and Women Health Limited informed that the National Company Law Tribunal (NCLT), New Delhi Bench, vide its order dated May 15, 2026, rejected the petition filed by M/s. Ramaa Capital (Operational Creditor) against the company under the Insolvency and Bankruptcy Code, 2016. The company received the order on May 22, 2026, and stated that this outcome has no impact on its financial, operational, or other activities.

Gaudium IVF and Women Health Limited announced an Earnings Conference Call to discuss its Audited Standalone and Consolidated Financial Statements/Results for the quarter and year ended March 31, 2026. The call is scheduled for Friday, May 29, 2026, at 12:00 P.M. IST.